E

Will bromodomain inhibitors and PROTACs make an impact?

A look at BET-bromodomain inhibitors, PROTACs, stapled proteins and more on MYC

September 4, 2019
E

Through the window on the MYC oncogene

What can we learn about the MYC transcription factor and oncogene in order to turn it into a viable target in oncology R&D?

August 21, 2019
E

Insights on the Jounce-Celgene collaboration and ICOS agonism

Thoughts and commentary on the Jounce-Celgene collaboration update and the emerging ICOS landscape

July 24, 2019
E

New developments in Sarcoma

A review of our Top 10 sarcoma results from ASCO19 plus commentary from a specialist KOL in this niche

July 23, 2019
E
AMG 596 EGFRvIII BiTE

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
E
Cambridge from Bay Bay Boston

An in-depth look at Neon’s updated neoantigen vaccine data

Insights on the updated phase 1b clinical data evaluating Neon's personalized vaccine NEO-PV-01 in combination with nivolumab in advanced cancers?

July 17, 2019
E

Will innate bispecifics make a difference in hematologic malignancies and solid tumours?

What can we learn from the recent data presented on Affimed's innate bispecific platform? A candid conversation with CEO, Dr Adi Hoess

July 11, 2019
E

How F-star are optimising bispecific antibodies for cancer treatment

Next generation IO molecules are likely to feature bispecific antibodies - can we address the weaknesses seen with immune agonist antibodies by switching modalities?

July 10, 2019
E

mRNA – the language of life

Can mRNA disrupt cancer therapy and boost responses beyond what we see with checkpoint therapy?

July 3, 2019
E

Navigating new opportunities in the IL-2 space

How is Synthorx's IL-2 cytokine THOR-707 different from other compounds in this niche?

June 26, 2019
E

How failure allows us to continually innovate

How the design of different cancer approaches can affect clinical performance

June 24, 2019
E

Alternative approaches to targeting cytokines

Can we employ red blood cells in allogeneic, off-the-shelf cellular therapy products for the treatment of cancer?

June 19, 2019
E

The value of biomarkers in rescuing oncology R&D

Update on PTCL developments and a possible new therapy that may be approved in this setting

June 14, 2019
E

Where’s the next exciting IO target coming from?

Working out which are markers versus valid targets is going to be key in IO progress. Here we look at one particular candidate...

May 20, 2019
E

Challenges of targeting KRASG12C and why Amgen’s AMG 510 may not be a winner

Exploring the many challenges associated with targeting KRASG12C and why we should temper enthusiasm for this niche

May 15, 2019
E

Can Silverback increase the Firepower of TLR agonists?

A review of the latest available TLR data and a look at an emerging biotech Silverback Therapeutics in this niche

May 9, 2019
E

Dancing with proteins

Proteins change shape, both temporally and also in response to different conditions. Can we use this information to develop novel cancer therapeutics? One company is exploring ways of achieving this.

May 6, 2019
E

There is a deeper world than this

A look at inducing apoptosis of cancer cells via CDK7 inhibition and the future for rational combo approaches.

May 1, 2019
E

Going back to basics

How next generation immunotoxin approaches can overcome capillary leak syndrome and be effective anti-cancer agents

April 29, 2019
E

Chipping away at cancer

Gritstone have evolved from start-up biotech to clinical stage oncology company. We catch up with them and discuss their latest progress.

April 25, 2019
E

Incysus Targets GBM with Gamma Delta T Cells

Can gamma delta T cells be effective as a therapeutic in GBM?

April 23, 2019
E

Going beyond BCMA as a target in multiple myeloma

Is there a better way to target myeloma than with BCMA alone? Data suggests there's plenty of room for improvement.

April 22, 2019
E

Targeting the adenosine pathway in cancer immunotherapy

A look a the updated adenosine pathway landscape and how it is progressing

April 18, 2019
E

Are 𝞬𝝳 T cells immuno-suppressive and should we delete them?

As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative

April 17, 2019
E

Targeting neutrophils for cancer immunotherapy

Neutrophils may be responsible for inducing immunosuppression and resistance to checkpoint therapies so how do we target them in the clinic?

April 15, 2019
E

Going beyond PARP inhibitors to improve cancer outcomes

We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...

April 11, 2019
E

The Future of Cancer Immunotherapy Biomarkers

With the help of a leading pathologist, we examine the challenges associated with PD-L1 and TMB as biomarkers for patient selection

April 9, 2019
E

How confident can we be in the reproducibility of the IMpassion130 results in TNBC?

Having a companion diagnostic is important for precision medicine, but can they accurately predict who is most likely to respond to cancer immunotherapy?

April 8, 2019
E

The Wisdom of Crowds

Mobbed posters indicate attendee interest, but is it justified?

April 3, 2019
E

Is the Apexigen anti-CD40 data hit or miss?

A look at Apexigen's anti-CD40 data in advanced pancreatic cancer - hit or miss?

April 2, 2019
E

Five early emerging trends to note from AACR19

What are the emerging trends from AACR19? What can we expect to see emerge over the next year?

April 1, 2019
E

10 things innovators should know about novel cancer targets at AACR19

Preview of AACR19 in Atlanta and what you need to know about ten novel cancer targets with data at the meeting.

March 25, 2019
E

AACR19 Preview of Cancer Immunotherapy Sessions – Part 2

In the second part of our review of the AACR19 cancer immunotherapy program, we take a look at more noteworthy sessions in Atlanta.

March 21, 2019
E

AACR19 Preview of Cancer Immunotherapy Sessions – Part 1

First part of a look at the immune-oncology track at AACR19 - there's a LOT going on this year!

March 20, 2019
E

Are gamma delta T cells the next wave of cell therapies?

Can we make novel allogeneic cell therapies with γδ T cells? We find out!

February 26, 2019
E

A Voyage of Discovery

Can γδ T cells be employed as a therapeutic against cancer?

February 25, 2019